David D. Meek - Net Worth and Insider Trading
David D. Meek Net Worth
The estimated net worth of David D. Meek is at least $4 Million dollars as of 2024-11-13. David D. Meek is the CEO of Mirati Therapeutics Inc and owns about 61,792 shares of Mirati Therapeutics Inc (MRTX) stock worth over $4 Million. David D. Meek is the Director of uniQure NV and owns about 20,252 shares of uniQure NV (QURE) stock worth over $135,790. David D. Meek is also the Chief Commercial Officer of Endocyte Inc and owns about 0 shares of Endocyte Inc (ECYT) stock worth over $0. Details can be seen in David D. Meek's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that David D. Meek has not made any transactions after 2024-06-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of David D. Meek
David D. Meek Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, David D. Meek owns 6 companies in total, including Entasis Therapeutics Holdings Inc (ETTX) , uniQure NV (QURE) , and Baxalta Inc (BXLT) among others .
Click here to see the complete history of David D. Meek’s form 4 insider trades.
Insider Ownership Summary of David D. Meek
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ETTX | Entasis Therapeutics Holdings Inc | 2019-06-19 | director |
| QURE | uniQure NV | 2024-06-13 | director |
| BXLT | Baxalta Inc | 2016-06-03 | EVP and President & Oncology |
 | | 2014-02-06 | Chief Commercial Officer |
| | 2023-01-17 | director & Chief Executive Officer |
| | 2023-10-16 | director |
David D. Meek Latest Holdings Summary
David D. Meek currently owns a total of 3 stocks. Among these stocks, David D. Meek owns 61,792 shares of Mirati Therapeutics Inc (MRTX) as of January 17, 2023, with a value of $4 Million and a weighting of 96.39%. David D. Meek owns 20,252 shares of uniQure NV (QURE) as of June 13, 2024, with a value of $135,790 and a weighting of 3.61%. David D. Meek also owns 0 shares of Endocyte Inc (ECYT) as of September 12, 2013, with a value of $0 and a weighting of 0%.
Latest Holdings of David D. Meek
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MRTX | Mirati Therapeutics Inc | 2023-01-17 | 61,792 | 58.70 | 3,627,190 |
| QURE | uniQure NV | 2024-06-13 | 20,252 | 6.71 | 135,790 |
| ECYT | Endocyte Inc | 2013-09-12 | 0 | 23.99 | 0 |
Holding Weightings of David D. Meek
David D. Meek Form 4 Trading Tracker
According to the SEC Form 4 filings, David D. Meek has made a total of 2 transactions in Mirati Therapeutics Inc (MRTX) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Mirati Therapeutics Inc is the sale of 3,179 shares on January 17, 2023, which brought David D. Meek around $134,726.
According to the SEC Form 4 filings, David D. Meek has made a total of 5 transactions in uniQure NV (QURE) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in uniQure NV is the sale of 2,229 shares on June 13, 2024, which brought David D. Meek around $11,413.
According to the SEC Form 4 filings, David D. Meek has made a total of 0 transactions in Endocyte Inc (ECYT) over the past 5 years. The most-recent trade in Endocyte Inc is the sale of 10,000 shares on September 12, 2013, which brought David D. Meek around $155,000.
Insider Trading History of David D. Meek
- 1
David D. Meek Trading Performance
David D. Meek Ownership Network
Ownership Network List of David D. Meek
Ownership Network Relation of David D. Meek
David D. Meek Owned Company Details
What does Entasis Therapeutics Holdings Inc do?
Who are the key executives at Entasis Therapeutics Holdings Inc?
David D. Meek is the director of Entasis Therapeutics Holdings Inc. Other key executives at Entasis Therapeutics Holdings Inc include 10 percent owner Theravance Inc , VP & Principal Fin & Acct Off Kristie Ann Wagner , and Chief Medical Officer David Altarac .
Entasis Therapeutics Holdings Inc (ETTX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Entasis Therapeutics Holdings Inc (ETTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Entasis Therapeutics Holdings Inc (ETTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Entasis Therapeutics Holdings Inc (ETTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Entasis Therapeutics Holdings Inc Insider Transactions
David D. Meek Mailing Address
Above is the net worth, insider trading, and ownership report for David D. Meek. You might contact David D. Meek via mailing address: 3000 Kent Avenue; Suite A1-100, West Lafayette In 47906.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
